VJHemOnc Podcast iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
Nov 17, 2023
John Gribben and Laurie Sehn discuss the use of antibody-drug conjugates (ADCs) in NHL. They explore challenges in comparing treatment options, modulation of target antigen, and FDA's changing requirements for drug approval. Recent updates in the use of ADCs, including decreased accelerated approvals and the importance of efficacy and safety, are also highlighted.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Clinical Trial Results in DLBCL
02:19 • 6min
Challenges in Comparing Treatment Options and Incorporating New Compounds into Treatment Algorithms in Lymphomas
07:56 • 4min
Modulation of Target Antigen and FDA's Changing Requirements for Drug Approval
11:54 • 3min
Recent updates with the use of antibody-drug conjugates in NHL
14:31 • 2min